TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.1, 2001-01, pp. : 75-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The therapeutic potential of TNF-α blockade in rheumatoid arthritis

By Paleolog Ewa

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 7, 2003-07 ,pp. : 1087-1095

Informa Healthcare

Access to resources Recommend Favorite

Anti-TNF Treatment in Rheumatoid Arthritis

Current Pharmaceutical Design, Vol. 17, Iss. 29, 2011-10 ,pp. : 3141-3151

Bentham Science Publishers

Access to resources Recommend Favorite

A Cost-Cost Study Comparing Etanercept with Infliximab in Rheumatoid Arthritis

By Nuijten M.J.C.

PharmacoEconomics, Vol. 19, Iss. 10, 2001-01 ,pp. : 1051-1064

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis

By Mikuls T.R.

Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. : 23-32

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis

By Coenen Marieke JH Toonen Erik JM Scheffer Hans Radstake Timothy RDJ Barrera Pilar Franke Barbara

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 761-773

Future Medicine

Access to resources Recommend Favorite